Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography

Thrombosis and Haemostasis

Volumn 88, Issue 6, 2002, Pages 1020-1025

  Schroeder, Verena ^a   Chatterjee, Tushar ^b   Mehta, Haresh ^b   Windecker, Stephan ^b   Pham, Trinh ^a   Devantay, Nicolas ^a   Meier, Bernhard ^b   Kohler, Hans Peter ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b BERN UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Coronary artery disease; Procarboxypeptidase; TAFI; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

ACUTE PHASE PROTEIN; CHOLESTEROL; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TRIACYLGLYCEROL;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOGRAPHY; ANTIGEN FUNCTION; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY STENT; CORRELATION FUNCTION; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HEMOSTASIS; HUMAN; HUMAN CELL; INFLAMMATION; LEUKOCYTE COUNT; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLISM; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE COUNT; TRANSLUMINAL CORONARY ANGIOPLASTY; TRIACYLGLYCEROL BLOOD LEVEL; VENOUS BLOOD;

EID: 12244252240     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613349     Document Type: Article

References (22)

1. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
2. Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity. A role in clot lysis in vivo. Circulation 1996; 93: 1328-30.
3. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
4. Von Dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-7.
5. Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Review. Thromb Haemost 1997; 78: 386-91.
6. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
7. Nesheim ME. TAFI. Review. Fibrinol Proteol 1999; 13: 72-7.
8. Mosnier LO, Von Dem Borne PA, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
9. Chetaille P, Alessi MC, Kouassi D, Morange PE, Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 2000; 83: 902-5.
10. Juhan-Vague I, Renucci JF, Grimaux M, Morange PE, Gouvernet J, Gourmelin Y, Alessi MC. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2000; 20: 2156-61.
11. Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, Tiret L, Juhan-Vague I. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: Evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001; 97: 2053-8.
12. Franco RF, Fagundes MG, Meijers JCM, Reitsma PH, LourenVo D, Morelli V, Maffei FH, Ferrari IC, Piccinato CE, Silva-Ir WA, Zago MA. Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: Relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 2001; 86: 510-7.
13. Brouwers GJ, Vos HL, Leebeek FWG, Bulk S, Schneider M, Boffa M, Koschinsky M, Van Tilburg NH, Nesheim ME, Bertina RM, Gómez Garcia EB. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels [Letter]. Blood 2001; 98: 1992-3.
14. Trégouet DA, Aubert H, Henry M, Morange P, Visvikis S, Juan-Vague I, Tiret L. Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms. Hum Genet 2001; 109: 191-7.
15. Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-9.
16. Cushman M, Folsom AR, Wang S, Heckbert SR, White RH, Aleksic N, Tsai MY, Tracy RP. A prospective study of thrombin activatable fibrinolysis inhibitor (TAFI) concentration and the TAFI-438 A polymorphism in relation to venous thromboembolism: The longitudinal investigation of thromboembolism etiology (LITE). Thromb Haemost 2001; supplement, XVIII ISTH Congress, Paris, abstract OC974.
17. Silveira A, Schatteman K, Goossens F, Moor E, Scharpé S, Strömqvist M, Hendriks D, Hamsten A. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-8.
18. Morange PE, Aubert H, Henry M, Nanni I, Aillaud MF, Alessi MC, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamstem A, Humphries SE, Juhan-Vague I. Evaluation of TAFI plasma antigen genotypes in myocardial infarction patients and controls from the north and south of Europe (Hifmech study). Thromb Haemost 2001; Supplement, XVIII ISTH Congress, Paris, abstract OC977.
19. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957: 17: 237-46.
20. Sato T, Miwa T, Akatsus H, Matsukawa N, Obata K, Okada N, Campbell W, Okada H. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol 2000; 165: 103-8.
21. Kato T, Akatsu H, Sato T, Matsuo S, Yamamoto T, Campbell W, Hotta N, Okada N, Okada H. Molecular cloning and partial characterization of rat procarboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2000; 44: 719-28.
22. Hudson I, De Bono DP. Levels of carboxypeptidase B (thrombin activatable fibrinolysis inhibitor, TAFI) following thrombolysis with streptokinase. Fibrinol Proteol 1998; 12 (Suppl. 1): 12 (abstract).